Population pharmacokinetic modeling for enterohepatic recirculation in Rhesus monkey

European Journal of Pharmaceutical Sciences

Volumn 26, Issue 2, 2005, Pages 151-161

  Shou, Magang ^a   Lu, Wei ^b   Kari, Prasad H ^a   Xiang, Cathie ^a   Liang, Yuexia ^a   Lu, Ping ^a   Cui, Dan ^a   Emary, W Bart ^a   Michel, Kimberly B ^a   Adelsberger, Jennifer K ^a   Brunner, Janice E ^a   Rodrigues, A David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Bile duct cannulation; Compartmental model; Enterohepatic recirculation; Non linear mixed effects modelling (NONMEM); Pharmacokinetics; Population pharmacokinetics

Indexed keywords

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILE DUCT; BILE SECRETION; CANNULATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ENTEROHEPATIC CIRCULATION; GALLBLADDER EMPTYING; MALE; MATHEMATICAL MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RHESUS MONKEY; SIMULATION;

ANIMALS; AREA UNDER CURVE; BILE; BIOTRANSFORMATION; COMMON BILE DUCT; ENTEROHEPATIC CIRCULATION; HALF-LIFE; INTESTINAL ABSORPTION; LIVER; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACOKINETICS; XENOBIOTICS;

EID: 23844526234     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2005.05.010     Document Type: Article

References (23)

1. U. Abshagen Effect of enterohepatic circulation on the pharmacokinetics of spironolactone in man Naunyn Schmiedebergs Arch. Pharmacol. 300 1997 281 287
2. J.G. Besner, R. Leclaire, and J.J. Roy Pharmacokinetics and metabolism of lonidamine in rats: evidence of enterohepatic recycling Drug Metab. Rev. 29 1997 219 234
3. R. Bullingham, A. Nocholls, and B. Kamm Clinical pharmacokinetics of mycophenolate mofetil Clin. Pharmacokinet. 34 1998 429 455
4. C. Csajka, C. Marzolini, K. Fattinger, L.A. Decosterd, J. Fellay, A. Telenti, J. Biollaz, and T. Bucli Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection Clin. Pharmacol. Ther. 73 2003 20 30
5. E. Dailly, S. Urien, E. Chanut, B. Claudel, N. Guerra, C. Fernandez, P. Jolliet, and M. Bourin Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance Prog. Neuro-Psychopharmcol. Biol. Psychiratry 26 2002 699 703
6. S.N. De Wildt Glucuronidation in humans: pharmacogenetic and developmental aspects Clin. Pharmacokinet. 36 1999 439 452
7. D. Duggan The disposition of sulindac Clin. Pharmacol. Ther. 21 1977 326 335
8. K. Elomaa, S. Ranta, J. Tuominen, and P. Lahteenmaki The possible role of enterohepatic cycling on bioavailability of norethisterone and gestodene in women using combined oral contraceptives Contraception 63 2001 13 18
9. E.L. Ette, C.A. Howie, A.W. Kelman, and B. Whiting Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies Pharm. Res. 12 1995 729 737
10. F. Ezzet, G. Krishna, D.B. Wexler, P. Statkevich, T. Kosoglou, and V.K. Bartra A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe Clin. Ther. 23 2001 871 885
11. T. Funaki Enterohepatic circulation model for population pharmacokinetic analysis J. Pharm. Pharmacol. 10 1999 1143 1148
12. G. Gieschke, H-U. Burger, B. Reigner, K.S. Blesch, and J.L. Sterimer Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients Br. J. Clin. Pharmacol. 55 2003 252 263
13. D. Hoglund, and M. Ohlin Effect modeling for drugs undergoing enterohepatic circulation Eur. J. Drug Metab. Pharmacokinet. 18 1993 333 338
14. A. Laurent Analysis in the rat of 4-hydroxynonenal metabolites excreted in bile: evidence of enterohepatic circulation of these byproducts of lipid peroxidation Chem. Res. Toxicol. 12 1999 887 894
15. R.L. Oberle, and G.L. Amidon The influence of gastric emptying and intestinal transit rates on the plasma level curve of cimetidine: an explanation for the double peak phenomenon J. Pharmacokinet. Biopharm. 15 1987 529 544
16. D. Ouellet, and G. Pollack Biliary excretion and enterohepatic recirculation of morphine-3-glucuronide in rats Drug Metab. Dispos. 23 1995 478 484
17. B. Ploeger, T. Mensinga, A. Sips, J. Meulenbelt, and J. DeJongh A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling Pharm. Res. 17 2000 1516 1525
18. M.S. Roberts, R.M. Magnusson, F.J. Burczynski, and M. Weiss Enterohepatic circulation. Physiological, pharmacokinetic and clinical implications Clin. Pharmacokinet. 41 2002 751 790
19. T. Shepard, D. Gannaway, and G. Lockwood Accumulation and time to steady state for drugs subject to enterohepatic cycling: a stimulation study J. Pharm. Sci. 12 1985 1331 1333
20. T. Shepard, R. Reuning, and L. Aarons Interpretation of area under the curve measurement for drug subject to enterohepatic cycling J. Pharm. Sci. 2 1985 227 228
21. C.E. Staatz, C. Willis, P.J. Taylor, and S.E. Tett Population pharmacokinetics of tacrolimus in adult kidney transplant recipients Clin. Pharmacol. Ther. 72 2002 660 669
22. T. Vree, and A.V.D. Ven Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans J. Pharm. Pharmacol. 51 1999 239 248
23. J.G. Wagner Unusual pharmacokinetics L.Z. Benet G. Levy BL. Ferraiolo Pharmacokinetics: A Modern View 1984 Plenum Press New York 173 189